Evaluation of p16ink4a overexpression in a large series of cervical carcinomas: Concordance with spf10-lipa25 pcr

International Journal of Gynecological Pathology

Volumn 33, Issue 1, 2014, Pages 74-82

  Pérez, Cristina ^a   Castillo, Marta ^b   Alemany, Laia ^c   Tous, Sara ^c   Klaustermeier, Joellen ^c   De Sanjose, Silvia ^c,d   Velasco, Julio ^a  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^b San Agustín Hospital   (United States)

^c Jarrio Hospital   (Spain)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

Cervical cancer; HPV; LiPA25 PCR; P16INK4a; SPF10

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; FORMALDEHYDE; PARAFFIN; VIRUS DNA;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE HYBRIDIZATION LINE PROBE ASSAY; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; TUMOR INVASION; UTERINE CERVIX CARCINOMA; VIRUS DETECTION; WART VIRUS; CARCINOMA; FEMALE; IN SITU HYBRIDIZATION; METABOLISM; PAPILLOMAVIRUS INFECTION; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX TUMOR; VIROLOGY;

CARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 84890434055     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e3182774546     Document Type: Article

References (41)

1. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
2. Munoz N, Castellsague X, de Gonzalez AB, et al. Chapter 1: HPV in the etiology of human ca ncer. Vaccine 2006;24(suppl 3): 1-10.
3. de Sanjose S, Quint Wim GV, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-56.
4. Clifford G, Franceschi S, Diaz M, et al. Chapter 3: HPV typedistribution in women with and without cervical neoplastic diseases. Vaccine 2006;24(suppl 3): 26-34.
5. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
6. Southern SA, Herrington CS. Disruption of cell cycle control by human papillomaviruses with special reference to cervical carcinoma. Int J Gynecol Cancer 2000;10:263-74.
7. Munger K, Basile JR, Duensing S, et al. Biological activities and molecular targets of the human papillomavirus E/ oncoprotein. Oncogene 2001;20:7888-98.
8. Shirodkar S, Ewen M, DeCaprio JA, et al. The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner. Cell 1992;68:157-66.
9. Berezutskaya E, Yu B, Morozov A, et al. Differential regulation of the pocket domains of the retinoblastoma family proteins by the HPV16 E7 oncoprotein. Cell Growth Differ 1997;8:1277-86.
10. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
11. Serrano M The Tumor Suppressor Protein p16INK4a Exp Cell Res 1997;237:7-13
12. Khleif SN, DeGregori J, Yee CL, et al. Inhibition of cyclin DCDK4/ CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA 1996;93:4350-4.
13. Negri G, Egarter-Vigl E, Kasal A, et al. p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations. Am J Surg Pathol 2003; 27:187-93.
14. von Knebel Doebertiz M. New markers for cervical dysplasia to visualize the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002;38:2229-42.
15. Klaes R, Friedrich T, Spitkousky D, et al. Overexpression of p16(INK4a) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92: 276-84.
16. Ordi J, Garcia S, del Pino M, et al. p16 INK4a immunostaining identifies occult CIN lesions in HPV-positive women. Int J Gynecol Pathol 2009;28:90-7.
17. Tsoumpou I, Arbyn M, Kyrgiou M, et al. p16 (INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009;35:210-20.
18. Carozzi F, Cecchini S, Confortini M, et al. Role of p16(INK4a) expression in identifying CIN2 or more severe lesions among HPV-positive patients referred for colposcopy after abnormal cytology. Cancer 2006;108:119-23.
19. Wang SS, Trunk M, Schiffiman M, et al. Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004;13: 1355-60.
20. Galgano MT, Castle PE, Atkins KA, et al. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol 2010;34:1077-87.
21. Dijkstra MG, Heideman DA, de Roy SC, et al. p16(INK4a) immunostaining as an alternative to histology review for reliable grading of cervical intraepithelial lesions. J Clin Pathol 2010;63:972-7.
22. Stoler MH. Advances in cervical screening technology. Mod Pathol 2000;13:275-84.
23. Molijn A, Kleter B, Quint W, et al. Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol 2005; 32(suppl 1): 43-51.
24. Iftner T, Villa LL. Chapter 12: human papillomavirus technologies. J Natl Cancer Inst Monogr 2003;31:80-8.
25. Santos M, Landolfi S, Olivella A, et al. p16 overexpression identifies HPV-positive vulvar squamous cell carcinomas. Am J Surg Pathol 2006;30:1347-56.
26. Agoff SN, Lin P, Morihara J, et al. p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol 2003;16:665-73.
27. Cubilla AL, Lloveras B, Alejo M, et al. Value of p16(INK4)(a) in the pathology of invasive penile squamous cell carcinomas: a report of 202 cases. Am J Surg Pathol 2011;35:253-61.
28. Kleter B, van Doorn LJ, ter Schegget J, et al. Novel shortfragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 1998;153:1731-9.
29. Kleter B, van Doorn L-J, Schrauwen L, et al. Development and clinical evaluation of highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999;37: 2508-17.
30. Landis JR, Koch GG. An application of hierarchical kappatype statistics in the assessment of majority agreement among multiple observers. Biometrics 1977;33:363-74.
31. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med 2005;37:360-3.
32. Feinstein AR, Cicchetti DV. High agreement but low kappa: I. The problemsof two paradoxes. J Clin Epidemiol 1990;43:543-9.
33. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2008;17:2536-45.
34. Ozgul N, Cil AP, Bozdayi G, et al. Staining characteristics of p16INK4a: is there a correlation with lesion grade or high-risk human papilloma virus positivity? J Obstet Gynaecol Res 2008;34:865-71.
35. Haidopoulos D, Partsinevelos GA, Vlachos GD, et al. p16INK4a is a strong biomarker for cervical intraepithelial neoplasia and invasive cervical carcinoma: a reappraisal. Reprod Sci 2009;16:685-93.
36. Kostopoulou E, Samara M, Kollia P, et al. Different patterns of p16 immunoreactivity in cervical biopsies: correlation to lesio n grade and HPV detection, with a review of the literatura. Eur J Gynaecol Oncol 2011;32:54-61.
37. Lesnikova I, Lidang M, Hamilton-Dutoit S, et al. p16 as a diagnostic marker of cervical neoplasia: a tissue microarray study of 796 archival specimens. Diagn Pathol 2009;4:22-28.
38. El Hamdani W, Amrani M, Attaleb M, et al. p16INK4a and E-cadherin immuno-histochemistry and EGFR point mutations analyses in invasive cervical cancer specimens from Moroccan women. Cell Mol Biol 2010;56(suppl): 1373-84.
39. Biedermann K, Dandachi N, Trattner M, et al. Comparison of real-time PCR signal-amplified in situ hybridization and conventional PCR for detection and quantification of human papillomavirus in archival cervical cancer tissue. J Clin Microbiol 2004;42:3758-65.
40. Greer CE, Peterson SL, Kiviat NB, et al. PCR amplification from paraffin-embedded tissues. Effects of fixative and fixation time. Am J Clin Pathol 1991;95:117-24.
41. Lesnikova I, Lidang M, Hamilton-Dutoit S, et al. Rapid, sensitive, type specific PCR detection of the E7 region of human papillomavirus type 16 and 18 from paraffin embedded sections of cervical carcinoma. Infect Agent Cancer 2010;5:2.